Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?
deadline 2026-12-15
confidence medium
tier 4 evidence
65%Asturna estimate
Resolution criterion
Yes if the FDA approves the BLA by 15 December 2026 (Drugs@FDA or the Vertex newsroom). A complete response letter, a postponement of the PDUFA date, or the absence of a decision by that date count as no.
Verified starting state
BLA accepted for accelerated approval, PDUFA date 30 November 2026, on the basis of proteinuria reduction. The BAFF/APRIL inhibitor class is crowding into this indication and the FDA has tightened its requirements on biomarker-based accelerated approvals. (1 June 2026)
What pushes it up
- The FDA has accepted the BLA for accelerated approval with a PDUFA date of 30 November 2026, which falls before the resolution deadline [1, 4].
- Vertex Pharmaceuticals is an established developer with significant resources to manage the BLA process [1].
What pushes it down
- The FDA has explicitly tightened its requirements for accelerated approvals based on surrogate biomarkers like proteinuria reduction, which is the basis for this BLA [Starting State].
- The BAFF/APRIL inhibitor class is becoming crowded, potentially leading to higher regulatory scrutiny of new entrants [Starting State].
- The narrow 15-day window between the PDUFA date and the resolution deadline means any postponement or standard three-month extension would result in a 'No' resolution [Starting State].
What would move this number most
The primary uncertainty is whether the FDA will find the proteinuria reduction data robust enough to meet its increasingly stringent standards for accelerated approval in this indication.
How this number is built
| Deadline | 2026-12-15 |
| Base rate | 64% |
| Best evidence | tier 4 · 3 article(s) used |
| Independent runs | 60 · 70 (spread 10 pts) |
| Confidence | medium |
| Evidence cap | not triggered |
| Last revised | 2026-10-09 13:24 |
| Model | gemini-3-flash-preview |
Sources consulted
Probability history
2026-10-09 13:24 65% 5 article(s) on file · gemini-3-flash-preview
- What pushes it up. The FDA has accepted the BLA for accelerated approval with a PDUFA date of 30 November 2026, which falls before the resolution deadline [1, 4].
- What pushes it up. Vertex Pharmaceuticals is an established developer with significant resources to manage the BLA process [1].
- What pushes it down. The FDA has explicitly tightened its requirements for accelerated approvals based on surrogate biomarkers like proteinuria reduction, which is the basis for this BLA [Starting State].
- What pushes it down. The BAFF/APRIL inhibitor class is becoming crowded, potentially leading to higher regulatory scrutiny of new entrants [Starting State].
- What pushes it down. The narrow 15-day window between the PDUFA date and the resolution deadline means any postponement or standard three-month extension would result in a 'No' resolution [Starting State].
- What would move this number most. The primary uncertainty is whether the FDA will find the proteinuria reduction data robust enough to meet its increasingly stringent standards for accelerated approval in this indication.
2026-10-06 09:18 72% 5 article(s) on file · openai/gpt-oss-20b (Groq)
- What pushes it up. BLA accepted for accelerated approval with a PDUFA date of 30 Nov 2026, well before the 15 Dec 2026 deadline (hand‑verified, tier 1)
- What pushes it down. FDA has tightened biomarker‑based accelerated approval requirements, raising the risk of a complete response letter or postponement (no evidence yet)
- What would move this number most. Whether the FDA issues a complete response letter or postpones the PDUFA date after the BLA acceptance.
2026-09-21 22:24 72% 8 article(s) on file · openai/gpt-oss-120b (Groq)
Reasons not recorded for this revision (detailed history has only been kept since recently).
2026-09-19 07:34 78% 6 article(s) on file · gemini-3-flash-preview
Reasons not recorded for this revision (detailed history has only been kept since recently).